Hypertriglyceridemia

Most lipid-lowering medications lack safety data for pregnant and lactating women, complicating management of hyperlipidemia and hypertriglyceridemia, but data suggest statins can be used for those at high risk for cardiovascular events.

For nearly 2 decades, George L. Bakris, MD, was a pillar of the Cardiometabolic Health Congress, sharing his expertise, passion and unwavering dedication to advancing cardiometabolic health.

Because the science underpinning medicine evolves so quickly, it is not uncommon for some doctors to manage patients based on old evidence that is no longer a best practice; this is called clinical inertia.

Late bedtime and too little or too much sleep were associated with higher odds for hypertension, hypertriglyceridemia and metabolic syndrome, according to a study published in Journal of the American Heart Association.

The National Lipid Association has issued a clinical consensus statement on the management of dyslipidemia in women of reproductive potential, with a focus on considerations for pharmacologic options, a speaker reported.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

Olezarsen, an antisense oligonucleotide targeting mRNA for apolipoprotein C-III, lowered triglycerides at 6 months for patients with familial chylomicronemia syndrome without excessive adverse events, researchers reported.

In patients with severe hypertriglyceridemia, plozasiran, a novel RNA interference agent, lowered apolipoprotein C-III and triglycerides and improved other lipid parameters, according to the final results of the phase 2b SHASTA-2 trial.

In two phase 2b trials, RNA interference agents were associated with reductions in triglycerides compared with placebo for patients with mixed hyperlipidemia.